KRAS and neoplasm: Notably, PA1233 is characterized by P53R282W mutation and KRASG12D mutation, while PA1644 is P53 wild-type and KRAS wild-type, suggesting that the anti-tumor effect of compound XII may be related to the P53 and KRAS characteristics of the tumors.